Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Brief summary (registry, in English)

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

What you commit to

• Study type: Interventional · Phase 2/3
• Planned participants: 1541
• From 19 Jul 2018 to the primary completion date, 29 May 2043
• 263 sites in 26 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (263)

Sites in registry order. Pick your city on the disease page to sort them by distance.